Methyl-2-pyridylphosphan | 125995-80-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Methyl-2-pyridylphosphan
• 英文别名: Methyl pyridine phosphine；methyl(pyridin-2-yl)phosphane
• CAS: 125995-80-4
• 化学式: C₆H₈NP
• 分子量: 125.11
• InChiKey: NKZAIFQLGGHAHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-pyridylphosphine 在 甲基锂 作用下， 以 乙醚 为溶剂， 反应 4.5h， 生成 Methyl-2-pyridylphosphan
  参考文献：
  名称：

  Spiegel, Gerd U.; Stelzer, Othmar, Chemische Berichte, 1990, vol. 123, # 5, p. 989 - 993

  摘要：

  DOI：

文献信息

• [EN] MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR<br/>[FR] MODULATEURS DU RÉGULATEUR DE LA CONDUCTANCE TRANSMEMBRANAIRE DE LA FIBROSE KYSTIQUE
  申请人：VERTEX PHARMA

  公开号：WO2017173274A1

  公开（公告）日：2017-10-05

  The present disclosure features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, W, X, Z, n, p, and Rings A and B are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present disclosure also features pharmaceutical compositions, method of treating, and kits thereof.

  本公开涉及一种具有化学式I的化合物：或其药用可接受的盐，其中R1、R2、W、X、Z、n、p以及环A和环B在此处被定义，用于治疗CFTR介导的疾病，如囊性纤维化。本公开还涉及药物组合物、治疗方法以及相关工具包。
• [EN] HETEROCYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
  申请人：NUVATION BIO INC

  公开号：WO2020210381A1

  公开（公告）日：2020-10-15

  Heterocyclic compounds as Weel inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供了作为Weel抑制剂的杂环化合物。这些化合物可能被用作治疗药物，用于治疗疾病，并且在肿瘤学中可能发挥特殊作用。
• Highly robust efficient catalyst for selective dehydrogenation of neat glycerol to lactic acid
  申请人：UNIVERSITY OF SOUTHERN CALIFORNIA

  公开号：US10202327B2

  公开（公告）日：2019-02-12

  A catalyst system includes a complex having formula I which advantageously has a sterically protecting N-heterocyclic carbene (NHC) carbene-pyridine ligand to handle harsh reactions conditions than many prior art catalysts: wherein M is a transition metal; o is 0, 1, 2, 3, or 4; R1 is a C1-6 alkyl, a C6-18 aryl, or an optionally substituted C5-18 heteroaryl. In a refinement, R1 is methyl, ethyl, butyl, n-propyl, isopropyl, n-butyl, sec-butyl, or t-butyl; R2, R3, R3′ are independently an optionally substituted C1-6 alkyl, halo (e.g., Cl, F, Br, etc), NO2, an optionally substituted C6-18 aryl, or an optionally substituted C5-18 heteroaryl; R4, R4′ are independently an optionally substituted C1-6 alkyl, halo, NO2, an optionally substituted C6-18 aryl, or an optionally substituted C5-18 heteroaryl; and X− is a negatively charge counter ion and L1, L2 are each independently a neutral ligand.

  催化剂体系包括具有式 I 的络合物，该络合物具有立体保护的 N-杂环碳烯（NHC）碳烯-吡啶配体，与许多现有技术的催化剂相比，该络合物能够处理苛刻的反应条件： 其中 M 是过渡金属；o 是 0、1、2、3 或 4；R1 是 C1-6 烷基、C6-18 芳基或任选取代的 C5-18 杂芳基。在改进型中，R1 是甲基、乙基、丁基、正丙基、异丙基、正丁基、仲丁基或叔丁基；R2、R3、R3′ 独立地是任选取代的 C1-6 烷基、卤代物（例如、Cl、F、Br 等）、NO2、任选取代的 C6-18 芳基或任选取代的 C5-18 杂芳基；R4、R4′ 独立地是任选取代的 C1-6 烷基、卤素、NO2、任选取代的 C6-18 芳基或任选取代的 C5-18 杂芳基；X- 是带负电荷的反离子，L1、L2 各自独立地是中性配体。
• Compositions and methods for the treatment and prevention of neurological disorders
  申请人：Yumanity Therapeutics, Inc.

  公开号：US11241417B2

  公开（公告）日：2022-02-08

  The invention provides compositions and methods for treating neurological disorders, such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer's disease, among others. Using the compositions and methods described herein, a patient having a neurological disorder, such as a neurological disorder associated with TAR-DNA binding protein (TDP)-43 aggregation, may be administered an inhibitor of cytochrome P450 (CYP450) isoform 51A1 (CYP51A1), also referred to herein as lanosterol 14-alpha demethylase, so as to treat an underlying etiology of the disorder and/or to alleviate one or more symptoms of the disease. The inhibitor of CYP51A1 may be a small molecule, anti-CYP51A1 antibody or antigen-binding fragment thereof, or a compound, such as an interfering RNA molecule, that attenuates CYP51A1 expression. Patients that may be treated using the compositions and methods described herein include those that express a mutant TDP-43 isoform containing a mutation associated with TDP-43-promoted aggregation and toxicity.

  本发明提供了治疗神经系统疾病的组合物和方法，如肌萎缩侧索硬化症、额颞变性和阿尔茨海默病等。使用本文所述的组合物和方法，可以给患有神经系统疾病（如与TAR-DNA结合蛋白（TDP）-43聚集相关的神经系统疾病）的患者施用细胞色素P450（CYP450）同工酶51A1（CYP51A1）的抑制剂，CYP51A1在本文中也称为羊毛甾醇14-α去甲基化酶，从而治疗该疾病的潜在病因和/或减轻该疾病的一种或多种症状。CYP51A1的抑制剂可以是小分子、抗CYP51A1抗体或其抗原结合片段，或者是减弱CYP51A1表达的化合物，如干扰RNA分子。可使用本文所述组合物和方法治疗的患者包括那些表达突变型 TDP-43 同工酶的患者，这种突变与 TDP-43 促进的聚集和毒性有关。
• PROCESS FOR THE PREPARATION OF METHYL-QUINOLINE DERIVATIVES
  申请人：ALKALOIDA VEGYESZETI GYAR

  公开号：EP0435993A1

  公开（公告）日：1991-07-10